A Telehealth Program Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap in Nursing Homes for Older Adults with Insulin-Treated Diabetes: The Trescasas Study
<b><i>Objective:</i></b> To assess the impact and feasibility of a telehealth program using continuous glucose monitoring (CGM) and a connected insulin pen cap (CIPC) in nursing homes for older adults with insulin-treated diabetes. <b><i>Research Methods:</i></b> This multicenter, prospective, sequential, single-arm study consisted of three phases: (1) baseline, blind CGM (<i>Freestyle Libre Pro®</i>); (2) intervention 1, CGM (<i>Freestyle Libre2®</i>) without alarms; and (3) intervention 2, CGM with alarms for hypo and hyperglycemia. Two telehealth visits from reference diabetes units were conducted to adjust antidiabetic treatments. Insulin treatment was tracked using the <i>Insulclock®</i> CIPC. The study's primary objective was to evaluate the reduction of hypoglycemia rate. <b><i>Results:</i></b> Of 82 eligible patients at seven nursing homes, 54 completed the study (age: 87.7 ± 7.1, 68-102 years, 56% women, duration of diabetes: 18.7 years, baseline glycated hemoglobin: 6.9% [52 mmol/mol]). The mean number of hypoglycemic events was significantly reduced from baseline (4.4) to intervention 1 (2.8; <i>P</i> = 0.060) and intervention 2 (2.1; <i>P</i> = 0.023). The time below range 70 mg/dL (3.9 mmol/L) significantly decreased from 3.7% at baseline to 1.4% at intervention 2 (<i>P</i> = 0.036). The number of insulin injections significantly decreased from baseline to intervention 1 (1.2 to 0.99; <i>P</i> = 0.027). Nursing home staff expressed a positive view of the program, greater convenience, and potential to reduce hypoglycemia with the <i>Freestyle Libre2®</i> CGM versus the glucometer. <b><i>Conclusions:</i></b> A telehealth program using CGM and a CIPC was associated with improved glycemic profiles among institutionalized older individuals with diabetes receiving insulin and was well perceived by professionals.
Authors
- Gloria Blázquez
- Cristina Abreu (ORCID: https://orcid.org/0000-0002-9238-443X)
- Fernando Gómez‐Peralta (ORCID: https://orcid.org/0000-0003-0106-0091)
- Andressa da Luz Silva (ORCID: https://orcid.org/0009-0006-2793-020X)
- Marcos Matabuena
- Estefanía Santos (ORCID: https://orcid.org/0000-0002-1194-7422)
- Araceli Frutos
- Benito Cañuelo
- Luisa Vega-Valderrama
- Marta García-Galindo
- Ana Franco-López
- Cristina López Mardomingo
Institutions
- Harvard University (US)
- Royal Institute and Observatory of the Spanish Navy (ES)
- Hospital General De Segovia (ES)
- Hospital Universitario de Burgos (ES)
- Gobierno de Navarra (ES)
- Amadeus (Spain) (ES)
- Universidad de Burgos (ES)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1089/dia.2024.0356
- Citations
- 4
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.43